Need help finding what you are looking for?
Contact Us
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1378549
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1378549
Cholangiocarcinoma Market, By Cancer Type, By Therapy Type, By Route of Administration, By Distribution Channel, and By Region
PUBLISHED:
PAGES: 156 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Global Cholangiocarcinoma market is estimated to be valued at US$ 423.2 Mn in 2023 and is expected to reach US$ 1,600.7 Mn by 2030, exhibiting a Compounded Annual Growth Rate (CAGR) of 20.9% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 423.2 Mn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 20.90% | 2030 Value Projection: | US$ 1,600.7 Mn |
Figure 1. Global Cholangiocarcinoma Market Share (%), By Therapy Type, 2023
Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that originates in the bile ducts. Cholangiocarcinoma is a relatively rare cancer which needs to be diagnosed at an advanced stage because the symptoms of the cancer often appears late until the disease is at its well-advanced stage. The exact cause of cholangiocarcinoma is unknown, but it is believed that factors such as chronic inflammation of the bile ducts, certain infections (e.g., with the liver fluke parasite), and certain risk factors (e.g., smoking, heavy alcohol use) may increase the risk of developing this cancer. Diagnosis typically involves a combination of imaging studies, such as CT scans, MRIs, and endoscopic retrograde cholangiopancreatography (ERCP), as well as tissue biopsies to confirm the presence of cancer. Treatment options for cholangiocarcinoma depends on the stage of the cancer and the patient's overall health. The treatments are surgery, radiation therapy, chemotherapy, and other targeted therapies. Prognosis for cholangiocarcinoma varies depending on the stage at which it is diagnosed, and early detection and intervention are crucial for improving outcomes.
Market Dynamics
Key players are engaged in research and development activities which is expected to drive the global cholangiocarcinoma market growth over the forecast period. For instance, in February 2022, Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, a Germany-based clinical research institution, initiated a clinical trial titled "A Phase II Study of Immunotherapy with Durvalumab and Tremelimumab in Combination with Capecitabine or Without Capecitabine in Adjuvant Situation for Biliary Tract Cancer". The study is currently in phase 2 which is estimated to get completed by December 2024.
Key features of the study:
- This report provides an in-depth analysis of the global cholangiocarcinoma market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cholangiocarcinoma market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include BridgeBio Inc., Sanofi, Eisai Co., Ltd., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Fresenius SE & Co. KGaA, Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Incyte, TRISALUS LIFE SCIENCES, INC., GENFIT, Johnson & Johnson Private Limited, Bliss Biopharmaceutical, Novartis AG, LES LABORATOIRES SERVIER, F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris.Inc), AstraZeneca, Compass Therapeutics, Inc, Otsuka Holdings Co., Ltd., and Senhwa Biosciences, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global cholangiocarcinoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cholangiocarcinoma market
Detailed Segmentation:
- Global Cholangiocarcinoma Market, By Cancer Type:
- Perihilar
- Distal
- Extrahepatic Cholangiocarcinoma
- Intrahepatic Cholangiocarcinoma
- Global Cholangiocarcinoma Market, By Therapy Type:
- Targeted Drug Therapy
- Pemigatinib
- Ivosidenib
- Futibatinib
- Infigratinib
- Chemotherapy
- 5-fluorouracil
- Gemcitabine
- Cisplatin
- Capecitabine
- Oxaliplatin
- Immunotherapy
- Pembrolizumab
- Others (Late phase pipeline drugs)
- Others (Pain Medications and others)
- By Route of Administration:
- Oral
- Subcutaneous
- Intravenous
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- Company Profiles
- BridgeBio Inc.
- Sanofi
- Eisai Co., Ltd.
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Fresenius SE & Co. KGaA
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- Incyte
- TRISALUS LIFE SCIENCES, INC.
- GENFIT
- Johnson & Johnson Private Limited
- Novartis AG
- LES LABORATOIRES SERVIER
- F. Hoffmann-La Roche Ltd
- Mylan N.V. (Viatris.Inc)
- AstraZeneca
- Compass Therapeutics, Inc
- Otsuka Holdings Co., Ltd.
- Senhwa Biosciences, Inc.
Product Code: CMI4435
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Cancer Type
- Market Snippet, By Therapy Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Recent Product Launches/Approvals
- Recent Trends
- Mergers, Acquisitions, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- PORTER's Analysis
4. Global Cholangiocarcinoma Market - COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Cholangiocarcinoma Market, By Cancer Type, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Extrahepatic Cholangiocarcinoma
- Perihilar
- Distal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Intrahepatic Cholangiocarcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
6. Global Cholangiocarcinoma Market, By Therapy Type, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Targeted Drug Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Pemigatinib
- Ivosidenib
- Futibatinib
- Infigratinib
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- 5- fluorouracil
- Gemcitabine
- Cisplatin
- Capecitabine
- Oxaliplatin
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Pembrolizumab
- Others (Late phase pipeline drugs)
- Others (Pain Medications and others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
7. Global Cholangiocarcinoma Market, By Route of Administration, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Oral
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Subcutaneous
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Intravenous
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
8. Global Cholangiocarcinoma Market, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- E-commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
9. Global Cholangiocarcinoma Market, By Region, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and By Y-o-Y Growth, By Region, 2018 - 2030, (US$ Mn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profiles
- BridgeBio Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sanofi
- Eisai Co., Ltd.
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Fresenius SE & Co. KGaA
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- Incyte
- TRISALUS LIFE SCIENCES, INC.
- GENFIT
- Johnson & Johnson Private Limited
- Bliss Biopharmaceutical
- Novartis AG
- LES LABORATOIRES SERVIER
- F.Hoffmann-La Roche Ltd
- Mylan N.V. (Viatris.Inc)
- AstraZeneca
- Compass Therapeutics, Inc
- Otsuka Holdings Co., Ltd.
- Senhwa Biosciences, Inc.
- Analysts' Views
11. Section
- References
- Research Methodology
- About us and Sales Contact
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.